EUVIMEDEUVIMED entdecken
Crossref

Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System

Sean R Miller, Rachel Tucker Gonzalez, William C Jackson, Megan E V Caram, Phoebe A Tsao, Kristian Stensland, Yashesh Shah, Daniel Wale, Ka Kit Wong, Benjamin L Viglianti, David Elliott, Tanner Caverly und 6 weitere

Journal of Nuclear Medicine · 2025-01 · 66 (1) · 75-83

DOI: 10.2967/jnumed.124.268555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.01.2025. Verfasst von Sean R Miller und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Staging, Glutamate Carboxypeptidase II, Positron-Emission Tomography. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) PET was approved by the U.S. Food and Drug Administration in 2020 for the staging of newly diagnosed prostate cancer, yet rates of adoption and real-world positivity rates are unknown. We characterized patients undergoing PSMA PET staging and describe positive findings in a large national cohort.

Methods

We identified all newly diagnosed prostate cancer patients in the national Veterans Health Administration from June 2020 to August 2023. Demographics, staging imaging reports, and cancer-related information were obtained from electronic medical record data. To assess positive findings, we chart-reviewed 1,994 patients (n = 657 low to intermediate risk) with staging PSMA PET reports available.

Results

Among 31,838 patients with newly diagnosed prostate cancer, 4,538 (14%) underwent PSMA staging. Use of PSMA staging increased rapidly from near 0 in early 2021 to approximately 70% of patients with high- or very-high-risk disease by August 2023. Among patients who were N0/M0 by conventional imaging, PSMA PET positivity rates (N1 or M1) were 5.9% for favorable intermediate risk, 8.2% for unfavorable intermediate risk, 14% for high risk, and 34% for very high risk.

Conclusion

PSMA PET staging for newly diagnosed prostate cancer increased rapidly in the Veterans Health Administration. Positivity rates were less than 10% in this large intermediate-risk cohort. These data confirm the utility of PSMA PET staging in high-risk disease and suggest that additional study is needed to refine patient selection in intermediate-risk disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm StagingGlutamate Carboxypeptidase IIPositron-Emission TomographyHumansMaleAgedMiddle AgedAntigens, SurfaceUnited StatesAged, 80 and over

Stichwörter der Autor:innen

PSMA PETprostate cancerstaging

Substanzen

Glutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, Surface

Autor:innen und Institutionen

  • Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
  • Department of Biostatistics, University of Michigan, Ann Arbor, Michigan.
  • Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.
  • Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
  • Section of Urology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.

Zitieren

APA

Miller, S. R., Gonzalez, R. T., Jackson, W. C., Caram, M. E. V., Tsao, P. A., Stensland, K., Shah, Y., Wale, D., Wong, K. K., Viglianti, B. L., Elliott, D., Caverly, T., Hofer, T. P., Saini, S., Green, M. D., Schipper, M., Dess, R. T., & Bryant, A. K. (2025). Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System. Journal of Nuclear Medicine, 66(1), 75-83. https://doi.org/10.2967/jnumed.124.268555

Vancouver

Miller SR, Gonzalez RT, Jackson WC, Caram MEV, Tsao PA, Stensland K, et al. Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System. Journal of Nuclear Medicine. 2025;66(1):75-83. doi:10.2967/jnumed.124.268555

BibTeX
@article{Miller2025,
  author = {Miller, Sean R and Gonzalez, Rachel Tucker and Jackson, William C and Caram, Megan E V and Tsao, Phoebe A and Stensland, Kristian and Shah, Yashesh and Wale, Daniel and Wong, Ka Kit and Viglianti, Benjamin L and Elliott, David and Caverly, Tanner and Hofer, Timothy P and Saini, Sameer and Green, Michael D and Schipper, Matthew and Dess, Robert T and Bryant, Alex K},
  title = {Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {1},
  pages = {75--83},
  doi = {10.2967/jnumed.124.268555}
}
Kostenlos starten →